Emmanuelle Bourbouloux

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography

Caroline Rousseau, Anne Devillers, Christine Sagan et al. · Journal of Clinical Oncology · 2006 · 310 citations · Full text

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

M. Campone, Vincent Lévy, Emmanuelle Bourbouloux et al. · British Journal of Cancer · 2009 · 97 citations · Full text

Brown fat in breast cancer patients: analysis of serial 18F-FDG PET/CT scans

Caroline Rousseau, Emmanuelle Bourbouloux, L. Campion et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2006 · 90 citations

Medical Imaging, Breast Cancer Patients, Medicine +9